Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions | Financial Buzz

Insulet Presents Positive Clinical Trial Results for the Omnipod Horizon Hybrid Closed-Loop System at the American Diabetes Association’s 78th Scientific Sessions

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader
in tubeless
insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), today announced that positive
results from the most recent clinical trial of the Omnipod®
Horizon™ Automated Glucose Control System (Omnipod Horizon
System) were presented during the American
Diabetes Association (ADA) 78th Scientific Sessions in Orlando. The
study demonstrated that the Omnipod Horizon System performed well and
was safe for over five days of use in adults, adolescents, and children
with type 1 diabetes.1-3

The study was conducted in a supervised hotel setting under free-living
conditions with unrestricted meals and moderate-intensity exercise and
included patients who use multiple daily injections or traditional tubed
insulin pumps as their standard therapy. Study participants spent
significantly less time in hypoglycemia, more time in the target glucose
range and had better overnight glycemic control compared to their
standard therapy. The investigational device includes features that
allowed study participants to customize their diabetes management by
adjusting their target blood glucose levels and insulin delivery.

“We recognize that everyone’s treatment needs are different, and the
Omnipod Horizon System provides individualized diabetes management to
address real world challenges,” said Dr. Jennifer L. Sherr, MD, PhD, of
Yale University School of Medicine. “One of the important features is
the ability for users to tailor the system for exercise and high fat
meals to maintain good glycemic control.”

During the study, glucose control was maintained in the target range (70
to 180 mg/dL) between 69% and 79% of the time overall, and between 74%
and 85% of the time during the overnight period, across all age groups.
Hypoglycemia was very low overnight, ranging from 0.7% and 1.3% of the
time, across age groups.

“In the era of personalized medicine, Insulet is committed to bringing
our innovative technology to the global diabetes community and our
clinical data give us confidence that the Omnipod Horizon System will be
a significant advancement in diabetes management,” said Dr. Trang Ly,
Senior Vice President and Medical Director. “We are very pleased that
for the second consecutive year, Omnipod Horizon System research was
highlighted in the official ADA Press Program based upon its overall
excellence in furthering research and advancing treatment for people
with diabetes.”

About Insulet Corporation:

Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an
innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a
needle. Insulet also leverages the unique design of its Pod, by
tailoring its Omnipod technology platform for the delivery of
non-insulin subcutaneous drugs across multiple therapeutic areas.
Founded in 2000, more than 140,000 users across the globe rely on
Insulet’s Omnipod Insulin Management System to bring simplicity and
freedom to their lives. For more information, please visit: www.insulet.com,
www.myomnipod.com
and www.omnipodeurope.com.*

*Starting July 1, 2018, Insulet will assume direct distribution of its
Omnipod Insulin Management System in Europe, including sales, marketing,
training and customer support activities. This will allow Insulet to be
closer to the diabetes community and identify opportunities to support
European customer needs over the long-term, as it already does in the
United States and Canada.

Forward-Looking Statement:

This press release may contain forward-looking statements
concerning Insulet’s expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 22, 2018 in the section entitled
“Risk Factors,” and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.

© 2018 Insulet Corporation. Horizon, Omnipod and the Omnipod logo are
trademarks or registered trademarks of Insulet Corporation. All rights
reserved.

1Buckingham BA, Sherr JL, Forlenza GP, Peyser TA, Lee JB,
O’Connor JB, Dumais B, Huyett LM, Layne JE, Ly TT. Safety and
Performance of the Omnipod® Hybrid Closed-Loop System
in Adults with Type 1 Diabetes Over Five Days Under Free-Living
Conditions. Presented at the ADA 78th Scientific Sessions,
June 22-26, 2018.

2Forlenza GP, Buckingham BA, Sherr JL, Peyser TA, Lee JB,
O’Connor JB, Dumais B, Huyett LM, Layne JE, Trang T. Ly TT. Safety and
Performance of the Omnipod® Hybrid Closed-Loop in
Adolescents with Type 1 Diabetes Over Five Days Under Free-Living
Conditions. To be presented at the ADA 78th Scientific
Sessions, June 22-26, 2018.

3Sherr JL, Forlenza GP, Buckingham BA, Peyser TA, Lee JB,
O’Connor JB, Dumais B, Huyett LM, Layne JE, Ly TT. Safety and
Performance of the Omnipod® Hybrid Closed-Loop System in
Children Ages 6-12 Years Over Five Days Under Free-Living Conditions. To
be presented at the ADA 78th Scientific Sessions 78th
Scientific Sessions, June 22-26, 2018.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180624005044/en/